Alnylam Onpattro’s Expanded Use Gets Weak Thumbs Up From US FDA Panel

 
• By Sarah Karlin-Smith
  
baseball player bunting
Two FDA advisors described Alnylam’s Onpattro ATTR cardiomyopathy data as a 'bunt single' in lukewarm positive panel. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers